A six-amino-acid cosmetic peptide copied from the nerve protein SNAP-25, sold in creams to soften expression lines around the eyes.
Also called Acetyl hexapeptide-8, Acetyl hexapeptide-3, Acetyl hexapeptide-8 amide, Argireline peptide, Ac-EEMQRR-NH2, AH-8, Botox in a jar
When Argireline's status or evidence changes, it's in the next morning's email.
Argireline is a lab-made copy of a six-amino-acid stretch at the start of SNAP-25, a protein nerve endings need to release the signal that makes a muscle contract. It was published in 2002 by researchers in Alicante, Spain, and is sold by the Spanish company Lipotec, which Lubrizol bought in 2012. The idea is that the decoy gets in the way of the release machinery, so the small muscles that crease the skin around the eyes pull a little less. Botox works on the same machinery, but by cutting SNAP-25 outright. SNAP-8 is the same peptide with two more amino acids added.
It has more human data than most cosmetic peptides, but the trials are small and short. Hospital researchers in China gave it to 45 of 60 adults for 4 weeks and found 48.9% had better eye wrinkles versus none on placebo. A 24-person NIH trial in people with eyelid spasm found it safe alongside Botox, with only a trend toward longer relief. Two other small tests found nothing: an independent 19-woman split-face study in Germany saw no difference between the Argireline side and the plain side, and a 21-woman trial in Indonesia, funded by a local cosmetics company, saw the placebo group improve as much as the Argireline group. The often-quoted 30% drop in wrinkle depth comes from the developers' own 2002 volunteer test, not an independent trial.
The biggest open question is whether enough of it gets through the skin. An FDA lab study found about 0.01% of a 10% cream reached the living skin layer and none reached the dermis. The US Cosmetic Ingredient Review panel judged it safe only up to 0.005% in 2025, far below the 10% used in the early tests. It is a cosmetic ingredient, not a drug, and injecting it is untested and has caused a serious infection.
What it binds to, and what happens inside the body after that, step by step.
To fire a muscle, a nerve ending fuses small sacs of acetylcholine with its outer membrane using a three-protein clamp called the SNARE complex, and SNAP-25 is one of those proteins. Argireline copies the start of SNAP-25 and competes for its place, so some clamps form badly and less signal is released. The 2002 paper showed this in lab neurosecretion assays, with a potency similar to Botox type A but much lower maximum effect. Whether enough peptide gets through the skin to do this in facial muscles has not been shown.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
Several small randomized trials exist, and they disagree. A 60-person hospital trial in China found fewer wrinkles after 4 weeks, and a 24-person Greek trial with about 6 people per group found better skin texture than no peptide at some time points, while an independent 19-woman German split-face study and a 21-woman Indonesian trial found no difference from the control. The 30% wrinkle-depth figure often quoted comes from the developers' own volunteer test, which reported no group size or placebo comparison in its abstract. No trial has run longer than about 3 months, and an FDA skin study found almost none of the peptide gets past the outer skin layer.
60 adults with periorbital wrinkles (3:1 Argireline to placebo), hospital study in Xi'an, China
Overall anti-wrinkle efficacy was 48.9% with Argireline versus 0% with placebo after 4 weeks of twice-daily use, and skin roughness fell only in the Argireline group.
Read the study24 people with blepharospasm getting Botox every 3 months; NIH trial with co-authors from a peptide manufacturer
No serious side effects; symptoms took 3.7 months to return with Argireline versus 3.0 months with placebo, a trend that was not statistically significant.
Read the study24 healthy volunteers in 4 groups of about 6, university study in Athens
Compared with no peptide, acetyl hexapeptide-3 improved one skin-roughness measure at day 20 and lowered water loss through the skin at days 20 and 40; that comparison was not reported as significant at day 60. Groups had about 6 people each.
Read the study19 women, double-blind split-face: serum with Argireline on one side, same serum without it on the other
After 4 weeks, wrinkle scores on the Argireline side were no better than on the plain side (p=0.829), and the author concluded its effect was not proven.
Read the study21 Indonesian women, 7 per group: Argireline cream, Matrixyl cream or placebo, 8 weeks
Crow's feet scores fell by similar amounts in all three groups, including placebo, and no skin measurement differed significantly; 2 of 7 in the Argireline group reported stinging. The trial was funded by Indonesian cosmetics company Paragon Technology and Innovation.
Read the studyHuman cadaver skin and hairless guinea pig skin in diffusion cells, FDA laboratory
After 24 hours with a 10% cream, most peptide washed off the surface, 0.01% reached the epidermis and none was found in the dermis.
Read the studyLab neurosecretion assays plus healthy women volunteers
Argireline blocked neurotransmitter release in lab assays, and a 10% emulsion reduced wrinkle depth by up to 30% after 30 days in volunteers. This was the developers' own test (co-authors from the peptide's maker), and the abstract gives no group size or placebo comparison.
Read the studyWhen a new Argireline study in people is published, the daily email covers it.
These are questions the published research has not answered.
No product containing Argireline is approved as a medicine by the FDA.
Sold in topical cosmetics, which FDA does not review for efficacy before sale. It is not an approved drug anywhere. Lubrizol owns the Argireline trademark after buying Lipotec in 2012. The US Cosmetic Ingredient Review panel concluded in 2025 that acetyl hexapeptide-8 amide is safe in cosmetics up to 0.005% and that data are insufficient to call it safe above that. Not named on the WADA list.
When the FDA or WADA changes Argireline's status, it's in the next morning's email.
No human half-life has been published for Argireline, so we do not draw a clearance curve. Half-lives quoted online for it are usually estimates from animal data.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
Both act on SNAP-25, but Botox cuts the protein inside the nerve and lasts months. Argireline is a weak competitor applied to the skin surface, and an FDA study found almost none reaches the dermis.
A 60-person trial in China found improvements and a 24-person trial in Greece found partial ones, but a 19-woman German split-face study and a 21-woman Indonesian trial found no difference from the control.
No published dose-comparison trial exists, and the CIR panel could only confirm safety up to 0.005%.
No study has tested injected Argireline, and one published case of injection led to a serious mycobacterial infection.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Lipotec sells both and says they block the nerve signal at two different steps, so the effects add up.
EvidenceThe only support is lab nerve-cell data in a Lipotec patent; no published human trial has tested the pair.
Formulators pair a peptide that acts on nerve release with one that acts on the muscle receptor.
EvidenceA 2026 L'Oreal study tested a serum with both plus gluconolactone, niacinamide and seaweed extract in 50 and 42 people and reported changes from baseline, so neither peptide's own effect can be separated out.
Sold mainly as a pre-dissolved cosmetic ingredient; no drug-grade storage guidance exists.
Follow the cosmetic product's packaging and expiry date; no independent stability data are published.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, every source linked, unsubscribe any time.